EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Split‐Cas9‐based targeted gene editing and nanobody‐mediated proteolysis‐targeting chimeras optogenetically coordinated regulation of Survivin to control the fate of cancer cells

Changping Deng iD, Shihui Li, Yuping Liu, Wen Bao, Chengnan Xu, Wenyun Zheng, Meiyan Wang iD, Xingyuan Ma iD

Clinical and Translational Medicine · 2023

DOI: 10.1002/ctm2.1382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2023. Verfasst von Changping Deng und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, P. R. China. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Precise regulation of partial critical proteins in cancer cells, such as anti‐apoptotic proteins, is one of the crucial strategies for treating cancer and discovering related molecular mechanisms. Still, it is also challenging in actual research and practice. The widely used CRISPR/Cas9‐based gene editing technology and proteolysis‐targeting chimeras (PROTACs) have played an essential role in regulating gene expression and protein function in cells. However, the accuracy and controllability of their targeting remain necessary.

Methods

Construction of UMUC‐3‐EGFP stable transgenic cell lines using the Sleeping Beauty system, Flow cytometry, quantitative real‐time PCR, western blot, fluorescence microplate reader and fluorescence inverted microscope analysis of EGFP intensity. Characterization of Survivin inhibition was done by using Annexin V‐FITC/PI apoptosis, calcein/PI/DAPI cell viability/cytotoxicity assay, cloning formation assay and scratch assay. The cell‐derived xenograft (CDX) model was constructed to assess the in vivo effects of reducing Survivin expression.

Results

Herein, we established a synergistic control platform that coordinated photoactivatable split‐Cas9 targeted gene editing and light‐induced protein degradation, on which the Survivin gene in the nucleus was controllably edited by blue light irradiation (named paCas9‐Survivin) and simultaneously the Survivin protein in the cytoplasm was degraded precisely by a nanobody‐mediated target (named paProtacL‐Survivin). Meanwhile, in vitro experiments demonstrated that reducing Survivin expression could effectively promote apoptosis and decrease the proliferation and migration of bladder cancerous cells. Furthermore, the CDX model was constructed using UMUC‐3 cell lines, results from animal studies indicated that both the paCas9‐Survivin system and paProtacL‐Survivin significantly inhibited tumour growth, with higher inhibition rates when combined.

Conclusions

In short, the coordinated regulatory strategies and combinable technology platforms offer clear advantages in controllability and targeting, as well as an excellent reference value and universal applicability in controlling the fate of cancer cells through multi‐level regulation of key intracellular factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsNeoplasmsHumansAnimalsSurvivinGene EditingProteolysisApoptosisDisease Models, Animal

Stichwörter der Autor:innen

Coordinated regulating to SurvivinFate of cancer cellsNanobody targeted degradationPhotoactivatable proteolysis and editing

Substanzen

Survivin

Autor:innen und Institutionen

  • State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, P. R. China.
  • Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, P. R. China.
  • Synthetic Biology and Biomedical Engineering Laboratory, Biomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical, Sciences and School of Life Sciences, East C…

ORCID-Profile: Changping Deng, Meiyan Wang, Xingyuan Ma

Zitieren

APA

Deng, C., Li, S., Liu, Y., Bao, W., Xu, C., Zheng, W., Wang, M., & Ma, X. (2023). Split‐Cas9‐based targeted gene editing and nanobody‐mediated proteolysis‐targeting chimeras optogenetically coordinated regulation of Survivin to control the fate of cancer cells. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1382

Vancouver

Deng C, Li S, Liu Y, Bao W, Xu C, Zheng W, et al. Split‐Cas9‐based targeted gene editing and nanobody‐mediated proteolysis‐targeting chimeras optogenetically coordinated regulation of Survivin to control the fate of cancer cells. Clinical and Translational Medicine. 2023. doi:10.1002/ctm2.1382

BibTeX
@article{Deng2023,
  author = {Deng, Changping and Li, Shihui and Liu, Yuping and Bao, Wen and Xu, Chengnan and Zheng, Wenyun and Wang, Meiyan and Ma, Xingyuan},
  title = {Split‐Cas9‐based targeted gene editing and nanobody‐mediated proteolysis‐targeting chimeras optogenetically coordinated regulation of Survivin to control the fate of cancer cells},
  journal = {Clinical and Translational Medicine},
  year = {2023},
  doi = {10.1002/ctm2.1382}
}
Kostenlos starten →